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Immune cells sense microbial products through Toll-
like receptors (TLR), which trigger host defense
responses including type 1 interferons (IFNs) secre-
tion. A coding polymorphism in the protein tyrosine
phosphatase nonreceptor type 22 (PTPN22) gene is
a susceptibility allele for human autoimmune and
infectious disease. We report that Ptpn22 selectively
regulated type 1 IFN production after TLR engage-
ment inmyeloid cells. Ptpn22 promoted host antiviral
responses and was critical for TLR agonist-induced,
type 1 IFN-dependent suppression of inflammation
in colitis and arthritis. PTPN22 directly associated
with TNF receptor-associated factor 3 (TRAF3) and
promotes TRAF3 lysine 63-linked ubiquitination.
The disease-associated PTPN22W variant failed to
promote TRAF3 ubiquitination, type 1 IFN upregu-
lation, and type 1 IFN-dependent suppression of
arthritis. The findings establish a candidate innate
immune mechanism of action for a human autoim-
munity ‘‘risk’’ gene in the regulation of host defense
and inflammation.
INTRODUCTION
Early immune responses to viral and bacterial infection are
critically dependent on cells of the myeloid lineage, including
dendritic cells (DCs) and macrophages (Akira et al., 2006).Upon recognizing pathogen-derived products, these ‘‘innate’’
immune cells engage multiple processes that mediate host pro-
tection, including myeloid cell activation, recruitment of effector
cells to sites of infection, and initiation of T and B lymphocyte
functions. Innate immune cells promote these processes in
part through elaboration of type 1 interferons (IFNs), including
IFN-b and members of the IFN-a family (Takeuchi and Akira,
2010). Type 1 IFNs signal through IFN-a receptor (IFNAR) to
induce upregulation of numerous genes that activate both innate
and adaptive host immunity (Stetson and Medzhitov, 2006).
Whereas type 1 IFNs are critical for host defense against infec-
tion, it is clear that they can also protect tissue by dampening
the effects of proinflammatory factors in diverse disorders
(Gonza´lez-Navajas et al., 2012; Kalliolias and Ivashkiv, 2010).
Pattern recognition receptors (PRRs) that sense conserved
molecular motifs in pathogen products are principal inducers
of type 1 IFNs. Type 1 IFN-inducing members of the Toll-like
receptor (TLR) family of PRRs are located either in endosomes
(TLR3, TLR7, TLR8, TLR9) or at the plasma membrane (TLR4)
(Takeuchi and Akira, 2010). Upstream of type 1 IFN promoters,
TLR signals activate transcription factors of the interferon
response factor (IRF) family. TLR3 and TLR4 require function of
IRF3, whereas TLR7 and TLR9 primarily act through IRF7 to
induce type 1 IFNs (Takeuchi and Akira, 2010). Nondegradative
K63-linked polyubiquitination of the E3 ubiquitin ligase TNF
receptor-associated factor 3 (TRAF3) is also required for IRF
activation and type 1 IFN induction after TLR ligation (Ha¨cker
et al., 2011). The mechanism whereby K63-linked poly-
ubiquitination of TRAF3 is activated by TLR signals remains
incompletely understood.
A single nucleotide polymorphism (rs2476601) in the PTPN22
gene is strongly associated with increased risk of humanImmunity 39, 111–122, July 25, 2013 ª2013 Elsevier Inc. 111
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PTPN22 is expressed widely in hematopoietic cell lineages
(Arimura and Yagi, 2010). Human PTPN22 encodes lymphoid
phosphatase (Lyp), an intracellular tyrosine phosphatase (Cohen
et al., 1999). Murine Ptpn22 encodes the Lyp ortholog, PEST-
domain enriched phosphatase (Pep) (Cloutier and Veillette,
1996). The major human PTPN22 allele (1858C) codes for
arginine at amino acid 620 position in PTPN22 (‘‘PTPN22R’’)
(Gregersen et al., 2006). The disease susceptibility allele,
1858T, encodes tryptophan-620 (‘‘PTPN22W’’).
Overexpression experiments and studies in Ptpn22/ T cells
strongly suggested that both PTPN22 in humans and Ptpn22 in
mice serve as negative regulators of T cell receptor signaling
(Hasegawaet al., 2004). Variant PTPN22Wdifferentially regulates
human lymphocyte antigen receptor activation thresholds (Rhee
and Veillette, 2012). However, the mechanisms by which altered
PTPN22W function in lymphocytes might contribute to diverse
PTPN22-associated diseases remain incompletely defined. Little
has been reported concerning PTPN22 function in nonlympho-
cytes. Zhang et al. reported hyperresponsiveness among DCs
harboring a knocked-in Pep variant that is orthologous to human
PTPN22W (Zhang et al., 2011). However, no innate immune cell
function has yet been established for endogenous Ptpn22 or for
the human disease-associated variant PTPN22W.
Here, we report that Ptpn22 connects TLR signaling in innate
immune cells with the induction of type 1 IFN-driven host
defense and immunoregulatory responses. We observed that
Ptpn22 positively regulated type 1 IFN production after TLR liga-
tion in myeloid cells. Moreover, Ptpn22 promoted type 1 IFN-
dependent processes in vivo, including innate and adaptive
cellular responses to viral infection, promotion of gut homeosta-
sis, and suppression of inflammatory arthritis. PTPN22 bound to
TRAF3 and positively regulated TLR-induced TRAF3 lysine 63
(K63)-linked polyubiquitination. Finally, we report that human
disease-associated variant PTPN22W exhibited reduced func-
tion with respect to TLR signaling, type 1 IFN production, and
immunoregulation.
RESULTS
Ptpn22 Positively Regulates TLR-Driven Type 1
Interferon Production in Myeloid Cells
In macrophages and DCs, TLRs engage bifurcating signaling
cascades that culminate in upregulation of type 1 IFNs and
proinflammatory cytokines (Takeuchi and Akira, 2010). To
address whether Ptpn22 regulates TLR signaling, we stimulated
bone marrow-derived macrophages (BMM) with lipopolysac-
charide (LPS), a TLR4 agonist (Akira et al., 2006). We observed
impaired induction of Ifnb1 and Ifna4 messenger RNA (mRNA)
in Ptpn22/ BMM (Hasegawa et al., 2004) (Figure 1A; see also
Figure S1A available online). Notably, we found no defects in
TLR4-induced upregulation of Tnf, Il1b, or other proinflammatory
cytokine transcripts known to be dependent upon NF-kB activa-
tion, inPtpn22/BMM (Figure 1A; Figure S1B). Similar to results
in Ptpn22/ macrophages, we observed impaired TLR4
agonist-stimulated upregulation of type 1 IFNs, but not of proin-
flammatory cytokines, in Ptpn22/ bone marrow-derived DCs
(BMDCs; Figure 1B; Figures S1D and S1E), and in RAW 264.7
cells, BMM, and human blood monocyte-derived macrophages112 Immunity 39, 111–122, July 25, 2013 ª2013 Elsevier Inc.(MDM) subjected to knockdown of Ptpn22 or PTPN22 with cell-
permeable antisense oligonucleotide (ASO) (Figure 1C; Figures
S1H, S1I, S1K, and S1N). Moreover, we found diminished
IFN-a, but normal TNF production after stimulation of Ptpn22/
Flt3 ligand-induced BMDCs (Flt3L-BMDCs) with polyU or CpG
(TLR7 or TLR9 ligand, respectively; Figure S1G). We observed
markedly decreased IFN-b production after stimulation of
Ptpn22/ BMM with LPS or the TLR3 agonist poly(I:C) (Fig-
ure 1D). Interestingly, we found impaired Ifnb1 induction in
Ptpn22/ BMM transfected with poly(I:C) (Figure S1O), which
stimulates type 1 IFN upregulation through engagement of
MDA5, an intracellular RNA receptor (Kato et al., 2006).
Together, these data indicated that Ptpn22 positively regulates
type 1 IFN induction signaled by a range of PRRs expressed in
multiple human and murine myeloid cell types in vitro. Loss of
Ptpn22 has no effect on induction of proinflammatory cytokines,
strongly suggesting that Ptpn22 selectively promotes subsets of
PRR signals.
Intraperitoneal administration of TLR agonists results in rapid
upregulation of type 1 IFNs and proinflammatory cytokines by
liver-resident myeloid cells (Seki et al., 2000). Upon injection of
LPS or poly(I:C) into Ptpn22/ mice, we observed marked
defects in hepatic Ifnb1 and Ifna4mRNA upregulation (Figure 1E;
Figure S1P), as well as reduced serum concentrations of IFN-b
(Figure 1F). However, serum TNF and interleukin-6 (IL-6) concen-
trations increased normally after LPS injection (Figure S1Q).
These data indicated that Ptpn22 selectively potentiates TLR-
induced type 1 IFN production in vivo.
We asked whether diminished TLR-driven type 1 IFN produc-
tion by Ptpn22/ myeloid cells and animals might result in
defective type 1 IFN-dependent responses. We found that
Ptpn22/BMMandBMDCs orPTPN22 knockdownMDMstim-
ulated with either LPS or poly(I:C) exhibited markedly impaired
upregulation of type 1 IFN-inducible genes, including Ifit1 and
Isg15 (Figures S1C, S1F, and S1J). We also observed that
Ptpn22 positively regulated induction of type 1 IFN-inducible
genes in vivo after LPS or poly(I:C) challenge (Figure S1R).
Further, TLR3- or TLR4-stimulated Ptpn22/ BMM showed
reduced upregulation of the type 1 IFN-dependent, costimula-
tory molecules CD86 and CD40 (Figure 1G; Figure S1S). These
findings indicated that PTPN22 or Ptpn22 potentiates TLR-medi-
ated type 1 IFN-inducible gene upregulation and cellular activa-
tion in vitro and in vivo.
Ptpn22 Promotes Optimal Antigen-Specific CD8+ T Cell
Expansion upon TLR Engagement
TLR signals might cooperate with antigen receptor and costimu-
latory molecule signals to promote optimal proliferation and
functional differentiation of cytolytic CD8 T lymphocytes in vivo
(Curtsinger et al., 2005). The TLR-induced ‘‘Signal 3’’ might be
mediated by type 1 IFN. To assess the role of Ptpn22 in TLR
agonist-promoted T lymphocyte responses, we adoptively
transferred wild-type (WT) OT-1 TCR transgenic T cells into WT
or Ptpn22/ hosts. Five days after injecting cognate antigen
(ovalbumin) together with poly(I:C), we quantified reporter OT-1
T cell proliferation and Granzyme B expression. We found that
OT-1 cells responding to OVA plus poly(I:C) in Ptpn22/ mice
displayed significantly reduced expansion (Figure 1H) and
impaired induction of Granzyme B expression (Figure 1I),
Figure 1. Ptpn22 Selectively Regulates TLR-
Induced Type 1 IFN Production
(A and B) WT and Ptpn22-deficient (Ptpn22/)
BMM (A) or BMDCs (B) were stimulated with LPS
(100 ng/ml) for 4 hr. Gene expression values relative
to Gapdh were determined by qPCR on total RNA.
(C) Human MDMwere treated with Control (Con) or
PTPN22 ASO for 48 hr. Cells were then stimulated
with LPS (100 ng/ml) for 1 and 4 hr. Gene expres-
sion values relative to RPL13A were determined by
qPCR on total RNA.
(D) BMM were stimulated with LPS or poly(I:C)
(p(I:C); 10 mg/ml) for 16 hr. IFN-b concentrations in
culture supernatant were quantified by ELISA. NS,
no stimulus. #, undetectable.
(E) qPCR on total liver RNA 4 hr after i.p. injection
of LPS (5 mg/kg) or p(I:C) (10 mg/kg) (n = 4 per
genotype).
(F) Serum IFN-b concentrations (mean ± SEM) were
measured by ELISA at 1 hr after i.p. injection of LPS
(left panel) or 4 hr after i.p. injection of p(I:C) (right
panel).
(G) BMM stimulated with LPS or p(I:C) for 16 hr.
Mean fluorescence intensity (MFI; obtained by
FACS) values for LPS stimulated conditions are
shown.
(H and I) WT OT-1 Tg CD8+ T cells (1 3 105) were
adoptively transferred into hosts of indicated
genotype. Mice were immunized with ovalbumin
(OVA) alone or with OVA plus p(I:C) (n > or = 7 per
genotype). On day 5, the numbers (H) and fractions
of Granzyme B+ (I) OT-1 T cells in draining lymph
nodes were detected by FACS. Data shown are
mean ± SEM (H and I). *p < 0.05, **p < 0.01, ***p <
0.001. Data are representative of two (C) or three
(A and B, and D–F) independent experiments with
similar results (mean ± SEM in A–E). See also
Figure S1.
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treated control animals. Ptpn22 was not required for the modest
OT-1 proliferation stimulated by antigen alone, nor was Ptpn22
required for antigen processing and presentation in vivo (Fig-
ure S2A). Ptpn22/ mice also displayed normal splenic DC
subsets compared to WTmice (Figure S2B). These findings indi-
cated that Ptpn22 regulates a T cell-extrinsic effect of poly(I:C)
on expansion of CD8+ T cells responding to antigen.
Ptpn22 Promotes Host Antiviral Responses
As type1 IFNsarecriticalmediatorsof antiviral hostdefense (Stet-
son and Medzhitov, 2006), we investigated a possible role for
Ptpn22 in antiviral immunity. Protective innate and adaptive im-
mune responses against lymphochoriomeningitis virus (LCMV)
and encephalomyocarditis virus (EMCV) depend upon type 1Immunity 39, 111IFN upregulation by pattern recognition
receptors, including TLRs and intracellular
RNA sensors such as MDA5 (Gitlin et al.,
2006; Jung et al., 2008; McCartney et al.,
2011; Zhou et al., 2010). We found that
one day after LCMV exposure, Ptpn22/
mice displayed reduced infection-induced
serum IFN-a and IFN-b concentrations(Figure 2A) andblunted activation of splenicCD8a+DCsandplas-
macytoid DCs (pDCs) (Figure 2B; Figures S2C and S2D). pDCs
are the primary producers of type I IFNsduring acute LCMV infec-
tion (Jung et al., 2008). We observed significantly fewer splenic
IFN-a-producing pDCs after LCMV infection in Ptpn22/ mice
compared toWTmice (Figures2Cand2D).However, thepercent-
age of TNF-producing pDCs after LCMV infectionwas unaffected
in Ptpn22/ mice (Figures S2E and S2F). Moreover, Ptpn22/
mice exhibited impaired expansion of LCMV-specific CD8+
Tcells (Figures2Eand2F). Finally,weobserved increasedmortal-
ity and viral titers in Ptpn22/mice infected with EMCV (Figures
S2G and S2H). Taken together, these data indicated that Ptpn22
promotes innate immune cell activation and cytotoxic T lympho-
cyte proliferation, as well as viral clearance and protection from
death after infection by select viruses.–122, July 25, 2013 ª2013 Elsevier Inc. 113
Figure 2. Ptpn22 Promotes Host Antiviral
Responses In Vivo
(A–F) Mice were i.p. inoculated with LCMV (23 105
PFU). (A) Serum IFN-a and IFN-b concentrations
were measured by ELISA at 24 hr after infection. (B)
Upregulation of CD86 and CD40 on splenic CD8a+
DCs (CD8a+CD11c+) or plasmacytoid DCs (pDCs;
B220+PDCA1+) was assayed by FACS at 24 hr after
infection. Fold increases in MFI (mean ± SEM) are
shown (n = 6 per genotype, (A) and (B). (C and D)
IFN-a expression in splenic pDCs at 24 hr after
LCMV infection was detected by intracellular
staining. (C) Numbers shown on representative
plots are percentages of pDCs staining positive for
IFN-a. (D) Percentages of IFNa+ pDCs in individual
animals; means ± SEM are indicated (n = 5 per
genotype). (E and F) Percentages of LCMV
tetramer+ CD8+ T cells in spleen at day 7 after
infection are shown (E) and means ± SEM are
indicated (F) (n > or = 12 per genotype). **p < 0.01,
***p < 0.001. Data are representative of three
independent experiments with similar results
(mean ± SEM in A, B, D, and F). See also Figure S2.
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of Arthritis
Mounting evidence implicates TLR signals and type 1 IFNs in
immunoregulatory and anti-inflammatory processes (Gonza´lez-
Navajas et al., 2012). To investigate the role of Ptpn22114 Immunity 39, 111–122, July 25, 2013 ª2013 Elsevier Inc.in poly(I:C)-driven immunoregulation, we
utilized a model of IL-1b-dependent in-
flammatory arthritis in which poly(I:C)
treatment ameliorates disease in a type 1
IFN-driven manner (Ji et al., 2002; Yarilina
et al., 2007). In the absence of poly(I:C),
WT and Ptpn22/ mice developed poly-
arthritis of equal severity after injection of
arthritogenic serum (Figure 3A). WT mice
exhibited dramatic reduction of serum-
induced arthritis after repeated poly(I:C)
treatment. In contrast, Ptpn22/ mice
exhibited robust arthritis despite poly(I:C)
treatment (Figure 3A). More severe
arthritis in poly(I:C)-treated Ptpn22/
mice correlated with increased synovial
leukocyte infiltration (Figure 3B). We also
observed reduced serum type 1 IFN
amounts, and lower synovial expression
of type 1 IFN-inducible gene Isg15, in
Ptpn22/ mice receiving poly(I:C) treat-
ment (Figures 3C and 3D). However,
poly(I:C) treatment of WT mice resulted
in a lower expression of synovial Il1b
than was observed in Ptpn22/ mice
(Figure 3D). In serum transfer arthritis,
poly(I:C) treatment suppresses synovial
IL-1b expression, and the suppressive
effects of poly(I:C) are type 1 IFN-depen-
dent (Corr et al., 2009; Yarilina et al.,
2007). Therefore, the synovial Il1b findingssuggested that Ptpn22 might inhibit synovial inflammation in
serum transfer arthritis by promoting type 1 IFN-dependent
downregulation of proinflammatory cytokines.
PTPN22 regulates signaling in T and B lymphocytes (Rhee
and Veillette, 2012). To ask whether adaptive immune cells
Figure 3. Ptpn22 Promotes poly(I:C)-Medi-
ated Suppression of Inflammatory Arthritis
(A–F) Mice (n = 3 per group) were injected i.p. with
K/BxN serum and were treated with vehicle or
with p(I:C) i.p. (A and E) Arthritis severity scores
(mean ± SEM) are shown. (B and F) Ankle joint
sections were stained with hematoxylin and eosin
(H&E). Scale bar represents 200 mm. (C) Serum
IFN-a and IFN-b (mean ± SEM) at day 11 were
measured by ELISA. (D) Gene expression (mean ±
SEM) relative to Gapdh in mouse synovium
was determined by qPCR. *p < 0.05, **p < 0.01,
***p < 0.001.
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suppression, we utilized T and B cell-deficient Rag1/ mice.
Rag1/ mice developed robust arthritis after serum transfer
(Figures 3E and 3F), as previously reported (Korganow et al.,
1999). Importantly, Rag1/ mice also showed poly(I:C)-driven
amelioration of arthritis, equivalent to that observed in WT
animals (Figures 3E and 3F). Together, these data indicated
that Ptpn22 promotes poly(I:C)-driven, type 1 IFN-mediated
suppression of inflammatory arthritis, and that adaptive im-
mune cells are not required to mediate Ptpn22-dependent
effects.
Ptpn22 PromotesMucosal Homeostasis in DSS-Induced
Colitis
Myeloid cell-produced type 1 IFNs protect intestinal epithelial
cells against mucosal injury (Katakura et al., 2005) in the
dextran sodium sulfate (DSS) mouse model of colitis (Okayasu
et al., 1990). In comparison with WT littermates, DSS-exposed
Ptpn22/ mice developed more severe colitis, as evidenced
by accelerated loss of body weight (Figure 4A) and diminished
colon length (Figure 4F; Figure S3). Histological examination
revealed more frequent ulceration and more extensive intra-
mural leukocyte infiltration in colons from Ptpn22/ mice
(Figure 4B). Further, Ptpn22/ mice exhibited reduced Mx1
but augmented Tnf and Il1b mRNA (Figure 4C) in colonic
mucosa. We also asked whether Ptpn22 potentiates TLR9-
driven, DC-mediated, type 1 IFN-dependent protection of
the colonic mucosa (Katakura et al., 2005). After serial CpGImmunity 39, 111–injection concomitant with DSS expo-
sure, control animals showed signif-
icant protection against weight loss,
colonic ulceration, and colon shortening.
Ptpn22/ mice displayed reduced pro-
tection after CpG treatment (Figures 4D
and 4F; Figure S3). Increased mucosal
ulceration in the colons of CpG-
treated, DSS-exposed Ptpn22/ mice
again correlated with markedly reduced
expression of the type 1 IFN-inducible
gene Mx1 and with upregulated Tnf
and Il1b (Figure 4G). Thus, Ptpn22
promotes both constitutive type 1 IFN-
dependent mucosal protection, and
TLR-induced, myeloid cell-mediated,type 1 IFN-dependent amelioration of intestinal injury in DSS
irritant colitis.
Ptpn22 Positively Regulates TLR-Triggered IRF3
Activation
We addressed themolecular mechanism for selective promotion
of TLR-induced type 1 IFN by Ptpn22. We stimulated Ptpn22-
deficient myeloid cells with TLR ligands and analyzed cell lysates
for activation of IRF3 and of the NF-kB pathway (Sato et al.,
2003). After LPS or poly(I:C) stimulation, we found reduced phos-
phorylation of IRF3 inPtpn22/BMM (Figures 5A and 5B). How-
ever, we observed no change in the kinetics of LPS-induced IkBa
degradation inPtpn22/BMM (Figure S4A). Notably, after TLR7
agonist PolyU stimulation, we found diminished IRF7 nuclear
translocation in Ptpn22/ Flt3L-BMDCs (Figure S4B). These
data indicated that Ptpn22 selectively regulates IRF3 and IRF7,
but not NF-kB, activation after TLR stimulation.
Type 1 IFNs signal through IFNAR to activate signal trans-
ducer and activator of transcription-1 (STAT1) (Stetson and
Medzhitov, 2006). In LPS- or poly(I:C)-stimulated Ptpn22/
BMM, we observed marked reduction in STAT1 phosphoryla-
tion (Figure 5C). However, treatment with recombinant IFN-a
induced normal STAT1 phosphorylation (Figure 5D), and IFN-b
treatment restored LPS-stimulated Isg15 and Mx1 expression,
in Ptpn22/ BMM (Figure 5E). These data indicated that
Ptpn22 is dispensable for signaling downstream of IFNAR.
Together, the findings strongly suggested that defective
type 1 IFN production, and not impaired IFNAR signaling,122, July 25, 2013 ª2013 Elsevier Inc. 115
Figure 4. Ptpn22 Promotes Mucosal Homeo-
stasis in DSS-Induced Colitis
(A–G) Mice were exposed to 3% DSS in drinking
water. Some mice also received CpG (10 mg per
animal) i.p. injection 3 hr before and at days 4 and 6
of DSS exposure (D–G). (A) Body weight (mean ±
SEM) of WT (n = 5) and Ptpn22/ (n = 4) mice,
relative to initial body weight, on days 18 after
exposure to 3% DSS in drinking water. (B and E)
Colonic sections were prepared and stained with
H&E. Colon ulceration (u), muscle hypertrophy (m)
and leukocyte infiltration (arrowheads) are indi-
cated. Scale bar represents 500 mm. (C and G)
Expression of Mx1, Il1b, and Tnf was measured in
colon harvested at days 4 (C) and 8 (G) by qPCR
(mean ± SEM). Values were relative to Rpl13. (D)
Body weight (mean ± SEM) of WT (n = 3) and
Ptpn22/ (n = 4) mice receiving CpG (10 mg per
mouse) i.p. injection 3 hr prior to, and at days 4 and 6
following start of, exposure to 3% DSS. (F) Colons
were harvested at day 810 after mice showed a >
20% drop in body weight, and length (mean ± SEM)
was measured. Each data point represents an indi-
vidual colon. *p < 0.05, **p < 0.01, ***p < 0.001. See
also Figure S3.
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cells and mice.
Ptpn22 Phosphatase Activity Is Not Required for
TLR-Triggered IRF3 Activation
PTPN22 tyrosine phosphatase activity is required for negative
regulation of antigen-receptor signaling (Cloutier and Veillette,
1999). To test the role of PTPN22 enzymatic activity in TLR
signaling, we studied PTPN22 C227S, a phosphatase-inactive
PTPN22 mutant (Cloutier and Veillette, 1999; Fiorillo et al.,
2010). We found that either WT or PTPN22 C227S expression in
Ptpn22/ BMM resulted in comparable augmented type 1 IFN
induction (Figure 5F). Moreover, we found no defects in either
IFN-b production by TLR4-stimulated RAW 264.7 cells treated116 Immunity 39, 111–122, July 25, 2013 ª2013 Elsevier Inc.withspecificPtpn22phosphatase inhibitors
I-C11 and4e (Stanford et al., 2011; Yu et al.,
2007) (Figure S4C) or in IRF3 phosphoryla-
tion or type 1 IFN induction by LPS-stimu-
lated BMM that were pretreated with the
specific inhibitor 4g (Stanford et al., 2011)
(Figures S4D and S4E). Together, these
results strongly suggested that Ptpn22
enzymatic activity is dispensable for TLR
signaling to type 1 IFN promoters.
Ptpn22 Interacts with TRAF3 and
Positively Regulates TRAF3 K63-
Linked Polyubiquitination
We speculated that PTPN22 might selec-
tively promote TLR signaling through
protein-protein association. We found that
PTPN22 coimmunoprecipitates with the E3
ubiquitin ligase TRAF3, a critical mediator
of TLR-induced type 1 IFN production(Ha¨cker et al., 2011), from human peripheral blood mononuclear
cell (PBMC)-derived dendritic cells (Figures 6A and 6B). The
PTPN22-TRAF3 association is likely direct, because purified
PTPN22 and TRAF3 specifically interact in vitro (Figure 6C).
Further, the PTPN22-TRAF3 association depends upon the
TRAF domain of TRAF3 but is independent of the TRAF3 RING
domain that mediates E3 ubiquitin ligase function (Figures S5A
and S5B). Notably, we observed no interaction between
PTPN22 and either TRAF2 or TRAF6, key mediators in TNFR
signaling and MyD88-dependent TLR signaling, respectively
(Cabal-HierroandLazo,2012;Chen, 2012) (FiguresS5CandS5D).
After TLR stimulation, K63-linked polyubiquitination of TRAF3
is required for downstream signals leading to production of type
1 IFNs (Tseng et al., 2010). We therefore investigated a possible
Figure 5. Ptpn22 Selectively Regulates TLR-
Induced IRF3 Activation
(A and B) LPS (A) or p(I:C) (B) stimulated BMM lysates
were probed with anti-phospho-IRF3 (p-IRF3) or anti-
total IRF3.
(C) Lysates from BMM stimulated with LPS or p(I:C)
for 4 hr were probed with anti-phospho-STAT1
(p-STAT1) and anti-total STAT1.
(D) BMM were stimulated with recombinant IFN-a
(1,000 U/ml). Whole cell lysates from indicated time
points were probed for phospho-STAT1 (p-STAT1)
and total STAT1.
(E) Gene expression in BMM stimulated with LPS
alone or with LPS plus recombinant IFNb (10 U/ml) for
6 hr was determined by qPCR. Expression values
(mean ± SEM) were relative to Rpl13.
(F) Ptpn22/ BMM were infected with empty retro-
virus (pMIGR), virus harboring PTPN22R, or phos-
phatase inactive variant PTPN22R-C227S for 48 hr.
Cells were then stimulated with LPS for 4 hr and
expression of Ifnb1 was determined by qPCR.
Expression values (mean ± SEM) were relative to
Gapdh. ***p < 0.001. Data are representative of three
independent experiments (AD). See also Figure S4.
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We observed marked reduction in K63-linked polyubiquitination
of TRAF3 from KLA-stimulated Ptpn22 ASO-treated RAW 264.7
cells (Figure 6D) and from LPS-stimulated Ptpn22/ BMM (Fig-
ure 6E). TRAF3 is required for suppression of the noncanonical
NF-kB pathway and loss of TRAF3 results in constitutive pro-
cessing of p100 to p52 (He et al., 2006; Zarnegar et al., 2008).
Interestingly, in Ptpn22/ BMM, we found no evidence of
p100 cleavage, similar to WT BMM (Figure S5E). Together, our
data thus suggested that although Ptpn22 specifically interacts
with TRAF3 and positively regulates TLR-induced K63-linked
polyubiquitination of TRAF3 in myeloid cells, Ptpn22 is dispens-
able for TRAF3-mediated suppression of the noncanonical
NF-kB pathway.
We hypothesized that the human disease-associated variant
PTPN22W might differentially regulate TLR signaling, compared
with the common variant PTPN22R. In 293T cells, we found that
coexpressed PTPN22R promoted TRAF3 K63-linked poly-
ubiquitination, whereas coexpressed PTPN22W did not (Fig-
ure 6F). Notably, PTPN22W showed reduced interaction with
TRAF3 compared to PTPN22R in 293T cells (Figure S5F). These
data suggested that variant PTPN22W functions as a hypo-
morph in promotion of TRAF3 K63-linked polyubiquitination.
Autoimmunity-Associated PTPN22W Fails to Promote
Type 1 IFN Induction
To investigate the possibility that PTPN22W could differentially
regulate myeloid signaling, we generated mice transgenic (Tg)Immunity 39, 11for human PTPN22R (Tg620R) or PTPN22W
(Tg620W) regulons. The transgenic mice
were interbred with Ptpn22/ animals.
Equivalent amounts of human PTPN22
mRNA in hematopoietic cells, and compa-
rable amounts of human PTPN22R and
PTPN22W in splenocytesanddendritic cells,were observed in Ptpn22+/Tg620R and Ptpn22+/Tg620Wmice
(Figures S6A–S6D). In addition, we found comparable amounts
of PTPN22 and Ptpn22 mRNA in spleen from Ptpn22+/Tg620R
mice (not shown). These findings suggested that the tissue
specificity and expression of transgenic PTPN22 parallel those
of endogenous Ptpn22 in the mice.
We compared innate immune cell functions in Tg620R
and Tg620W mice that carry either one or two Ptpn22 null
alleles. We found that, after LPS stimulation, BMDCs from
Ptpn22/Tg620R mice exhibited increased Ifnb1 expression
compared to BMDCs from Ptpn22/Tg620W mice (Figure 7A).
Similarly, BMM from Ptpn22+/Tg620R mice exhibited
augmented LPS-stimulated upregulation of Ifnb1 and Ifna4
compared to BMM fromPtpn22+/Tg620W animals (Figure S6E).
In addition, we found that upregulation of activation markers
CD80 and CD40 was augmented by LPS stimulation in
Ptpn22+/Tg620R BMM, but not in Ptpn22+/Tg620W BMM
(Figure S6F). Collectively, these data suggested that compared
to PTPN22R, PTPN22W fails to promote TLR-driven type 1
IFN upregulation and type 1 IFN-driven myeloid cell activation.
We examined the role of PTPN22W in type 1 IFN-dependent
modulation of inflammatory arthritis (see Figure 3A). We found
that after receiving arthritogenic serum, both Ptpn22/Tg620R
and Ptpn22/Tg620W mice developed arthritis of com-
parable severity. Ptpn22/Tg620R mice showed amelioration
of arthritis when injected repeatedly with poly(I:C). In
contrast, Ptpn22/Tg620W mice exhibited persistent arthritis
despite poly(I:C) treatment (Figure 7B). Compared with1–122, July 25, 2013 ª2013 Elsevier Inc. 117
Figure 6. Ptpn22 Specifically Interacts with
TRAF3 and Positively Regulates TLR-
Induced K63-Linked Polyubiquitination of
TRAF3
(A and B) Lysates from PBMC-derived DCs were
incubated with control immunoglobulin G, anti-
PTPN22 antibody (A), or anti-TRAF3 antibody (B)
followed by immunoprecipitation (IP) and immu-
noblotting with indicated antibodies.
(C) His pulldown from mixtures of His-PTPN22R
with GST or with GST-TRAF3.
(D) RAW 264.7 cells were treated with cell-perme-
able antisense oligonucleotide (ASO) against
Ptpn22 or with inverse Ptpn22 sequence control
(Con) ASO for 48 hr. Cells were then stimulated with
10 ng/ml Kdo2-lipid A (KLA) and K63-linked poly-
ubiquitination of TRAF3 was detected by IP and IB
with indicated antibodies.
(E) K63-linked polyubiquitination of TRAF3 in WT
and Ptpn22/ BMM after LPS stimulation.
(F) IP and IB were performed on lysates from
HEK293T cells transiently transfected with
expression plasmids encoding indicatedmolecules
to detect K63-linked polyubiquitination of TRAF3.
Ub, ubiquitin. Data are representative of two (D) or
three (AC, E, F) independent experiments. See
also Figure S5.
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PTPN22 Promotes Type 1 Interferon ProductionPtpn22/Tg620R animals, increased leukocyte infiltration
was observed in the synovium of Ptpn22/Tg620W mice
receiving poly(I:C) treatment (Figure 7C). Moreover, we found
reduced serum type 1 IFN concentrations and synovial Isg15
expression, but increased synovial Il1b expression in
Ptpn22/Tg620W mice compared to Ptpn22/Tg620R ani-
mals after poly(I:C) treatment (Figures 7D and 7E). Taken
together, the data suggested that PTPN22R, but not
PTPN22W, can promote poly(I:C)-driven suppression of in-
flammatory arthritis.
PTPN22W Carriers Show Reduced Type 1 IFN Response
to LPS
We sought evidence that PTPN22W differentially regulates TLR
signaling in human primary cells. We compared LPS-stimulated
PBMC from healthy donors who were either carriers of the
PTPN22 risk variant (PTPN22R/PTPN22W; ‘‘R/W’’) or age-118 Immunity 39, 111–122, July 25, 2013 ª2013 Elsevier Inc.matched noncarriers (‘‘R/R’’). We found
no differences in PTPN22 amounts
in PBMC-derived DCs (PBMC-DCs) or
PBMC obtained from PTPN22W carriers
and noncarriers (Figure S6G; data not
shown). However, we observed signifi-
cantly reduced STAT1 phosphorylation
in PBMC from PTPN22W carriers after
LPS stimulation (Figure S6H). Moreover,
gene expression analysis revealed that,
compared with cells from noncarriers,
upregulation of type 1 IFN-inducible
genes was significantly reduced in
PBMC-DCs from PTPN22W carriers
(Figures 7F). In contrast, LPS-inducedexpression of proinflammatory cytokines was similar in
PBMC-DCs from PTPN22W carriers and noncarriers (Figures
7F; Figure S6I). Taken together, these findings strongly
suggested that primary cells from PTPN22W carriers have
a selective defect in TLR-induced type 1 IFN-dependent
signaling and gene expression.
DISCUSSION
Here, we establish that Ptpn22 connects microbial pattern
sensing by innate immune cells with the induction of host
defense and immunoregulatory responses mediated by type 1
IFNs. Our findings indicate that Ptpn22 is critical for efficient up-
regulation of type 1 IFNs after TLR ligation in myeloid cells; that
Ptpn22 promotes type 1 IFN-dependent processes, including
myeloid cell activation in response to viral infection,maintenance
of gut homeostasis, and suppression of inflammatory arthritis
Figure 7. Disease-Associated PTPN22W Variant Exhibits Reduced Function in Promoting Type 1 Interferon Production
(A) BMDCs from indicated mice were stimulated with LPS (100 ng/ml) for 4 hr, and gene expression relative to Gapdh was determined by qPCR (mean ± SEM).
(BE) Mice were injected i.p. with K/BxN serum alone or with p(I:C) i.p. (n = 3 per group). (B) Arthritis severity scores (mean ± SEM) are shown. (C) Ankle joint
sections were stained with hematoxylin and eosin (H&E). Scale bar represents 200 mm. (D) Serum IFN-a and IFN-b (mean ± SEM) at day 11 were measured by
ELISA. (E) Gene expression relative to Gapdh in mouse synovium was determined by qPCR (mean ± SEM).
(F) PBMC-DCs from healthy donors carrying PTPN22W (R/W, n = 17) and noncarriers (R/R, n = 18) were stimulated with LPS (1 mg/ml) for 4 hr and gene expression
was analyzed by qPCR. Expression values (mean ± SEM) are relative to GAPDH. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S6.
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PTPN22 Promotes Type 1 Interferon Productionin vivo; and that Ptpn22 binds to, and potentiates K63-linked
polyubiquitination of, TRAF3, a central promoter of TLR signaling
leading to upregulation of type 1 IFNs. Remarkably, the humandisease-associated variant PTPN22W exhibits reduced function
in the promotion of TRAF3 K63-linked polyubiquitination and of
type 1 IFN production in response to TLR signals.Immunity 39, 111–122, July 25, 2013 ª2013 Elsevier Inc. 119
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PTPN22 Promotes Type 1 Interferon ProductionZhang et al. reported on myeloid cell functions in mice
harboring a murine Ptpn22 (‘‘619W’’) variant that is orthologous
to human PTPN22W (Zhang et al., 2011). In 619W knockin
DCs, Zhang et al. found augmented activation marker upregula-
tion after LPS stimulation and increased capacity to activate
antigen-specific T cells in vitro. In addition, Zhang et al. noted
reduced stability of the 619W variant. In contrast to Zhang
et al., our findings indicate that Ptpn22 deficiency results in
diminished TLR-dependent myeloid cell activation, both in vitro
and in vivo. Notably, we found no alteration in the ability of
Ptpn22/ DCs to take up, process, and present antigen in the
absence of a TLR stimulus in vivo. Incomplete degradation
and/or unknown biochemical features of the 619W variant stud-
ied by Zhang et al. might explain why 619W does not phenocopy
the effects of Ptpn22 deficiency.
Zhang et al. also described enhanced proteasome-mediated
degradation of the human PTPN22W variant in T cells. In
contrast with Zhang et al., but in agreement with a recent report
(Vang et al., 2012), we found no alteration in stability of the
PTPN22W variant expressed in either murine or human cells.
Differences in biochemical behavior between human PTPN22W
and the mouse Ptpn22 619W variant, and/or in cell-type-
specific variations in protein stability, might underlie the dis-
crepancies between our findings and those reported by Zhang
et al. Additional variation in experimental results might arise
from differences in PTPN22 detection antibodies used.
Because we find that PTPN22W expression is associated
with reduced TLR signaling and myeloid cellular activation, par-
allel to findings observed with Ptpn22 deficiency, the PTPN22W
variant might be viewed as a hypomorph with respect to these
functions.
Our data lend support to an emerging model wherein TRAF3
promotes TLR-induced type 1 IFNs and proinflammatory cyto-
kines through distinct mechanisms (Ha¨cker et al., 2011).
PTPN22 positively regulates TLR-induced type 1 IFN production
dependent upon nondegradative K63-linked polyubiquitination
of TRAF3 and upon IRF3 activation (Tseng et al., 2010). By
contrast, PTPN22 is dispensable for TLR-induced upregulation
of proinflammatory cytokines, which requires TRAF3 degrada-
tion via K48-linked ubiquitination to activate NF-kB. Further
analysis of the TRAF3-PTPN22 interaction will be required to
understand how PTPN22 selectively potentiates type 1 IFN-
inducing TRAF3 function in a PTPN22 phosphatase activity-
independent manner. Possibly, PTPN22 recruits additional
TRAF3-activating proteins. Impaired recruitment of such effec-
tors arising from reduced PTPN22W association with TRAF3
could contribute to the observed defects in PTPN22W capacity
to promote TRAF3 functions.
Our findings raise the intriguing possibility that enhanced sus-
ceptibility to disease in PTPN22W carriers could result from
defective type 1 IFN-mediated host resistance to infection. For
example, the PTPN22W-associated syndrome of Type 1 Dia-
betes (T1D) has long been associated with viral infection (Boet-
tler and von Herrath, 2011). Loss of TLR3, a type 1 IFN-inducing
sensor for viral double-stranded RNA (dsRNA), renders animals
susceptible to rapid T1D onset after infection with b cell-tropic
EMCV (McCartney et al., 2011). In addition, islet expression of
IFNAR signaling inhibitor suppressor of cytokine signaling 1
(SOCS1) potentiates Coxsackie B virus-induced T1D (Flodstro¨m120 Immunity 39, 111–122, July 25, 2013 ª2013 Elsevier Inc.et al., 2002). Together with our data showing that Ptpn22 posi-
tively regulates TLR signaling and promotes type 1 IFN-driven
antiviral responses, these observations suggest that reduced
function variant PTPN22W could result in diminished human
host-protective responses to diabetogenic viral infection.
Positive regulation of interferogenic TLRsignals byPtpn22also
suggests that Ptpn22 could regulate innate immunity to bacterial
pathogens. Consistent with this idea, PTPN22W carriage in
humans is associated with increased risk of invasive infections
with the Gram-positive bacterium S. pneumoniae (Chapman
et al., 2006). Induction of type 1 IFNs and type 1 IFN-dependent
genes in alveolar macrophages by S. pneumoniae contributes
to the clearance of bacteria (Koppe et al., 2012). Intriguing data
also suggest a role for TLR-induced type 1 IFNs in innate immune
responses to Gram-negative bacteria (Rathinam et al., 2012).
These observations suggest that an evolutionary advantage
conferred by PTPN22 might extend beyond avoiding exces-
sive activation of T and B lymphocytes, to the promotion of pro-
tective innate immune responses against a range of infectious
agents.
Type 1 IFNs play complex roles in inflammatory and autoim-
mune diseases (Gonza´lez-Navajas et al., 2012; Kalliolias and
Ivashkiv, 2010). In some autoimmune syndromes (e.g., systemic
lupus erythematosus [SLE]), type 1 IFNs might accelerate tissue
injury (Niewold, 2011). However, type 1 IFNs can also exert
potent anti-inflammatory effects; these have been observed in
colitis, multiple sclerosis, autoimmune diabetes, inflammatory
arthritis, and in some models of SLE (Hron and Peng, 2004;
Katakura et al., 2005; Rother et al., 2009; Sanford and Lyseng-
Williamson, 2011; Sobel and Ahvazi, 1998; Wu and Peng,
2006). Our data indicate that Ptpn22 promotes inflammation
suppression in models of colitis and synovitis wherein type 1
IFN-inducing TLR agonists can ameliorate tissue injury (Katakura
et al., 2005; Yarilina et al., 2007). Mechanisms whereby type 1
IFNs can suppress function of key cytokines such as IL-1b in
inflammatory states include downregulation of IL-1R expression,
upregulation of IL-1R antagonist, and blockade of IL-1 produc-
tion (Kalliolias and Ivashkiv, 2010). Our finding that PTPN22W
is a reduced function variant suggests a general mechanism
whereby human carriers could manifest increased inflammation
in response to autoimmune or infectious stimuli.
Together, our findings document that PTPN22 positively regu-
lates a TLR-triggered, type 1 IFN-inducing pathway in myeloid
cells and that variant PTPN22W exhibits reduced function in
this pathway. Previous work has shown that Ptpn22 also serves
as a regulator of proximal lymphocyte antigen-receptor signaling
(Rhee and Veillette, 2012). The relative contributions of PTPN22
function in innate or adaptive immune responses to the pathol-
ogy associated with human syndromes such as rheumatoid
arthritis, T1D, and thyroiditis remain to be established.
EXPERIMENTAL PROCEDURES
Mice
Ptpn22/ mice, crossed >10 times to C57BL/6 strain, have been described
(Hasegawa et al., 2004). All mice were maintained under specific pathogen-
free conditions and all studies were conducted in accordance with Institutional
Animal Care and Use Committee-approved protocols at the University of
Minnesota (Minneapolis, MN) and the La Jolla Institute for Allergy & Immu-
nology (LIAI, La Jolla, CA).
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PTPN22 Promotes Type 1 Interferon ProductionSubjects
Frozen healthy donor PBMC for this study were obtained from the study, Risk
Factors for the Severity of Infectious Mononucleosis Due to Primary Epstein-
Barr Virus Infection in University Students (Mono 5), which was approved by
the University of Minnesota Institutional Review Board (0608M90593).
LCMV Infection
Mice were injected intraperitoneally (i.p.) with 2 3 105 plaque-forming units
(PFU) LCMV Armstrong. IFN-a and IFN-b were measured in sera 24 hr after
LCMV infection by ELISA (PBL Biomedical Laboratories). Splenic DC activa-
tion was detected at 24 hr after LCMV exposure by FACS analysis. Intracellular
IFN-a or TNF staining of splenocytes was performed after a 3 hr incubation
with brefeldin A (eBioscience). Cells were stained with DC markers, followed
by fixation with Cytofix/Cytoperm buffer (BD). Subsequently, cells were per-
meabilized by using Perm/Wash buffer (BD) and incubated with anti-IFN-a
(clone RMMA-1, PBL) or anti-TNF (eBioscience). To enumerate LCMV-specific
T lymphocytes, we harvested splenocytes 7 days after infection and stained
with T-select H-2Db LCMV tetramer-KAVYNFATC (Beckman Coulter). Sam-
ples were acquired on a LSR II flow cytometer (BD Biosciences) and analyzed
with FACSDiva software.
Serum-Transfer System and Evaluation of Arthritis
Serum-transferred arthritis was induced by i.p. injection, on days 0 and 2, of
150 ml of pooled serum obtained from adult K/BxN mice. Poly(I:C) (150 mg)
or saline (150 ml) were injected i.p. every other day starting one day after serum
injection. Ankle thickness was measured with a caliper (J15 flat feeler). Each
limb was scored on a scale from 0 to 3.
DSS-Induced Colitis
DSS (molecular weight, 36–50 kDa; MP Biochemicals) was dissolved in
water to provide a working solution of 3% (weight/volume). Mice were given
free access to this solution for 10 days to induce acute colitis. Mice were
weighed daily. On day 10, or when mice lost more than 20% of the initial
body mass, colons were removed and measured, photographed and
prepared for histology. Colons used for RNA analyses were obtained on
day 3 after DSS exposure or at day 7 in experiments examining the effects
of CpG on colitis.
PBMC and PBMC-DC Stimulation
Previously frozen PBMC from healthy subjects were thawed and resuspended
at 13 106 cells/ml in RPMI-1640 with 10% FBS. Cells were cultured for 1 hr at
37C before stimulated with LPS (1 mg/ml) for 4 hr. PBMC-DCs were resus-
pended at 1 3 106 cells/ml in RPMI-1640 with 10% FBS and stimulated with
LPS (1 mg/ml) for 4 hr. Cells were then harvested for gene expression and
immunoblotting analysis.
Real-Time Quantitative PCR
RNA was isolated using TRIzol (Invitrogen), and cDNA was synthesized using
iScript (Bio-Rad), according to the manufacturer’s instructions. Real-time PCR
was performed as described in the Supplemental Experimental Procedures.
Immunoblotting and Immunoprecipitation
Immunoblotting and immunoprecipitation were performed as described in the
Supplemental Experimental Procedures.
Statistical Analysis
Data are presented as mean ± SEM. Multiple group comparisons were done
by one-way analysis of difference (ANOVA) with a Bonferroni multiple-
comparison posttest. Two-tailed Student’s t test was used to compare two
independent groups. For all tests, a p value less than 0.05 was considered
statistically significant. Prism GraphPad software v5.0 was used for statisti-
cal analyses.
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